Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Inhibitory-cell killer immunoglobulin-like receptors (KIR) negatively regulate natural killer (NK) cell–mediated killing of HLA class I–expressing tumors. Lack of KIR-HLA class I interactions has been associated with potent NK-mediated antitumor efficacy and increased survival in acute myeloid leuke...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Romagné, Francois, André, Pascale, Spee, Pieter, Zahn, Stefan, Anfossi, Nicolas, Gauthier, Laurent, Capanni, Marusca, Ruggeri, Loredana, Benson, Don M., Blaser, Bradley W., Della Chiesa, Mariella, Moretta, Alessandro, Vivier, Eric, Caligiuri, Michael A., Velardi, Andrea, Wagtmann, Nicolai
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2009
Gaiak:
Immunobiology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2756126/
https://ncbi.nlm.nih.gov/pubmed/19553639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-02-206532
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak